07/12/2025
Corona Remedies IPO Review | Strong Pharma Play!, Apply or Avoid ? GMP, Listing Gain, Financials, Profitability, Risks, Valuation & Strategy Explained
Corona Remedies IPO Review | Complete Analysis (GMP, Valuation, Financials & Final Verdict)
In this video, we breakdown the Corona Remedies IPO, a fast-growing Indian pharma company with 71+ brands across women’s healthcare, cardio-diabeto, pain management, urology, respiratory care & nutrition.
💊 What You Will Learn
✔ Business model & product portfolio
✔ Strong financial growth (65% profit jump!)
✔ Clean balance sheet & strong ROE/ROCE
✔ Valuation check — Fair or expensive?
✔ GMP trends & listing gain chances
✔ Should you apply or avoid as an investor?
✔ Best strategy for retail / long-term / listing gain investors
📌 IPO Key Details
💰 Issue Size: ₹655.37 Cr (Offer For Sale)
🎯 Price Band: ₹1008 – ₹1062
🧾 Lot Size: 14 Shares (₹14,868 Minimum Investment)
🗓️ Open: 8 Dec 2025 | Close: 10 Dec 2025 | Listing: 15 Dec 2025
🎯 Final Verdict
Corona Remedies IPO has:
🔥 Strong financials
💊 Growing pharma demand
📈 Robust distribution network
💼 Clean balance sheet
📌 So for long-term investors — YES
📌 For listing gain hunters — GOOD chance
🔍 Tags / Keywords (Copy-Paste in Description)
Corona Remedies IPO review, Corona Remedies IPO analysis, Corona Remedies listing gain, Corona Remedies GMP today, Corona Remedies IPO apply or avoid, best IPO December 2025, upcoming IPO in India, latest IPO review, GMP update, IPO for listing gain, pharma IPO India, Corona Remedies valuation, Corona Remedies financials.
